Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma

摘要: Bevacizumab and cetuximab both improve treatment efficacy when administered with chemotherapy for metastatic colorectal carcinoma (mCRC). Cetuximab has enhanced in Kras wild-type tumors. However, inferior outcomes have been demonstrated concerning the concurrent use of bevacizumab chemotherapy. There is an urgent need to define optimal sequence these two agents. With regard pre-clinical data that increased VEGF expression associated acquired resistance anti-EGFR antibody, we performed a retrospective analysis on patients who received bevacizumab-containing regimens after failure mCRC. From January 2006 December 2011, mCRC our institution were reviewed. Patients eligible further if following criteria met: i) mCRC; ii) as immediate prior treatment; iii) index line iv) imaging conducted response evaluation. Outcome measures included median progression-free survival (mPFS) objective rate (ORR). Targeted adverse events recorded accordance prospective observational cohort studies; BRiTE BEAT studies. Fifty reviewed 18 them met analysis. After follow-up 12.1 months, mPFS total group was 26.3 weeks (95% CI, 19.5–33.0 weeks) ORR 38.9%. Two (11.1%) had hypertension required additional anti-hypertensive drugs one patient did not survive due bowel perforation. No arterial thromboembolic (ATEs), post-operative wound-healing complications (POWHCs) or grade III/IV bleeding observed. In mCRC, modest activity manageable toxicity.